[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Correction
September 20, 2006

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial—Correction

JAMA. 2006;296(11):1355. doi:10.1001/jama.296.11.1355

Additional Study Group Member: In the Original Contribution entitled “Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial” published in the July 5, 2006, issue of JAMA (2006;296:56-63), the following name should appear. On page 63, under the Varenicline Phase 3 Study Group, “Raymond Niaura, PhD, Transdisciplinary Research, Butler Hospital, Providence, RI” should appear at the end of the list.

×